Market Data
Market Cap₹177.95 Cr.
52W High₹124.68
Current Price₹111.77
52W Low₹59.69
Down from 52W High10.4 %
Face Value₹10
Performance
ROCE9.97 %
ROE8.76 %
EPS (TTM)₹0.71
EPS Prev Qtr₹2.26
EPS Last Year₹0.45
EBITDA Qtr₹5.17 Cr.
Book Value₹52
Financial Health
Debt/Equity1.94
Debt/Profit22
Total Assets₹375.54 Cr.
Dividend Yield1.07 %
Promoter Holding50.86 %
Earning Power5.98 %
Valuation
Stock P/E24.62
Industry P/E33.3
Price to Book2.16
Price to Sales0.53
Graham Number₹72.7
Key Metrics
__derived
1
Face Value
₹10
About Bal Pharma Ltd
Healthcare · Pharmaceuticals
Bal Pharma Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹177.95 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 34.5% YoY, Profit grew 442.9% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 65.88 | 74.02 | 87.69 | 84.08 | 88.62 |
| ↳ QoQ Growth | - | +12.4% | +18.5% | -4.1% | +5.4% |
| Expenses | 62.33 | 70.57 | 81.37 | 76.57 | 83.45 |
| Operating Profit | 3.54 | 3.46 | 6.32 | 7.51 | 5.17 |
| OPM % | 5.37% | 4.67% | 7.21% | 8.93% | 5.83% |
| Other Income | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 |
| Interest | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| EBITDA | 6.06 | 5.73 | 9.55 | 10.57 | 7.95 |
| EBITDA Margin % | 9.2% | 7.74% | 10.89% | 12.57% | 8.97% |
| Profit Before Tax | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 0% | 0% | 0% | -12.11% | 0% |
| Net Profit | 0.21 | 0.72 | 1.79 | 3.6 | 1.14 |
| ↳ QoQ Growth | - | +242.9% | +148.6% | +101.1% | -68.3% |
| EPS | 0.12 | 0.45 | 1.12 | 2.26 | 0.71 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 311.67 | 334.41 |
| Expenses | 290.84 | 311.96 |
| Operating Profit | 20.83 | 22.46 |
| OPM % | 6.68% | 6.72% |
| Other Income | 1.93 | 1.65 |
| Interest | 16.82 | 17.24 |
| Depreciation | 11.08 | 11.34 |
| Profit Before Tax | 5.94 | 6.87 |
| Tax % | -6.57% | -5.68% |
| Net Profit | 6.32 | 7.25 |
| EPS | 3.95 | 4.54 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
34.7%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
9.37%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 15.9209 | 15.92 |
| Reserves | 61.495 | 66.31 |
| Borrowings | 150.38 | 159.51 |
| Other Liabilities | 107.89 | 133.8 |
| Total Liabilities | 335.6903 | 375.54 |
| Fixed Assets | 86.8149 | 76.75 |
| CWIP | 2.7858 | 7.42 |
| Investments | 2.47 | 2.08 |
| Other Assets | 243.62 | 289.29 |
| Total Assets | 335.6903 | 375.54 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 20.315 |
| Cash from Investing Activity | -14.9169 |
| Cash from Financing Activity | -7.8424 |
| Net Cash Flow | -2.4443 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 252.99 |
| ROCE % | 9.64% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 50.86% | 50.86% | 50.86% | 50.86% |
| FIIs % | 0.22% | 0.14% | 0.14% | 0.15% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 32.97% | 33.02% | 32.84% | 32.86% |
| No. of Shareholders | 15,774 | 15,520 | 15,214 | 14,974 |
Major Shareholders (>1%)
- Shailesh SiroyaPromoter and Promoter Group17.24%
- Micro Labs LimitedPromoter and Promoter Group12.64%
- Anita SiroyaPromoter and Promoter Group6.59%
- Prakash Chandra JainPublic Shareholding3.44%
As of 2026-06-30View all shareholders →